ArticleFrontiers in endocrinology2026
Narrative medicine approach for assessing the emotional experience of children and adolescents treated with daily rhGH and their caregivers.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recombinant human growth hormone (rhGH) therapy is a long-term, injective treatment, which can be burdened by emotional burden in patients and their caregivers. Narrative medicine can help the medical team to identify patients who are experiencing this negative emotional burden. Aims of this study were: 1. To investigate the emotional experience and the Health-Related Quality of life (HRQoL) of children and adolescents treated with daily rhGH and their caregivers through a narrative medicine approach. 2. To identify the factors influencing the emotional experience. Methods: Patients on rhGH therapy for at least one year were included. Two trained psychologists asked each of the patients and their caregivers three open-ended questions. Data on emotional experience, acceptance of therapy, satisfaction and awareness of treatment, adherence, discomfort towards peers, therapy-related stress, future plans were extrapolated. Patient and parental HRQoL were also assessed. Results: Fifty-three pediatric patients were recruited (mean age 12.3 ± 2.87 years; 62.3% male; 30.2% prepubertal). Distress/anxiety was reported in 41.5% of cases. Discomfort toward peers and therapy-related stress were reported in 24.5% and 49.1% of cases, respectively, and both correlated negatively with patients' emotional experience (p=0.019 and p=0.000, respectively) and acceptance of therapy (p=0.015 and p=0.001, respectively). Patient's emotional experience was influenced by stress (OR 0.02, 95%CI 0.004-0.132, p= 0.000) and patient's acceptance of therapy (OR 10.7, 95%CI 3.13-36.5, p=0.000). These latter results were confirmed by multivariate analysis (stress: OR 0.028, 95%CI 0.003-0.251, p=0.001; patient acceptance of therapy: OR 13.1, 95%CI 2.25-76.88, p=0.004, respectively, independently of age and sex. Conclusion: The emotional experience of patients on daily rhGH is negatively affected by non-acceptance of therapy and therapy-related stress. The narrative medicine approach is useful in early identification of emotional burden and promote implementation of strategies to improve psycho-social health for both patients and caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.